H.C. Wainwright has recently initiated Candel Therapeutics Inc (CADL) stock to Buy rating, as announced on December 2, 2022, according to Finviz. Earlier, on November 19, 2021, BMO Capital Markets had ...

GET MORE AI-GENERATED SIGNALS: January 01, 2025, 03:10 am ET, BY Rick W.- Contributor| Editor: Thomas H. Kee Jr. ( Follow on ...

Candel Therapeutics Inc (CADL) stock saw a decline, ending the day at $8.63 which represents a decrease of $-0.12 or -1.37% from the prior close of $8.75. The stock opened at $8.55 and touched a low ...

Reveal insider sentiment with alternative data that tracks buy and sell trades made by top managers and company directors.

The company’s stock price soared after its prostate cancer drug CAN-2409, met the primary endpoint in a Phase III study. On Wednesday, Candel Therapeutics, Inc. (NASDAQ:CADL) announced results ...

CADL’s Zacks Rank and Stocks to Consider Candel currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks from the drug/biotech industry are Bristol Myers BMY, Pfizer PFE and Gilead ...

Candel Therapeutics (NASDAQ:CADL) stock rocketed as much as 217% Wednesday after the company reported positive Phase 3 results for its drug candidate CAN-2409 in the treatment of localized ...

Candel shares are moving lower on Friday after the company priced its $80 million underwritten public offering of shares and pre-funded warrants.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...